This page contains brief information about recombinant human papillomavirus (HPV) quadrivalent vaccine and a collection of links to more information about the use of this vaccine, research results, and ongoing clinical trials.
Use in Cancer
Recombinant human papillomavirus (HPV) quadrivalent vaccine is approved to prevent some conditions caused by certain types of HPV. The vaccine protects against four different types of HPV.
It is used in individuals aged 9 to 26 years to prevent the following:
- Anal cancer.
- Cervical cancer.
- Vaginal cancer.
- Vulvar cancer.
- Lesions that sometimes lead to anal, cervical, vaginal, or vulvar cancer.
- Genital warts.
Recombinant HPV quadrivalent vaccine is no longer available in the United States. It is still used in other countries.
More About Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
MedlinePlus Information on Human Papillomavirus (HPV) Vaccine – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
HPV Infections Targeted by Vaccine Decrease in U.S.
Vaccine Reduces HPV Infections in Young Men
Clinical Trials Accepting Patients
Find Clinical Trials for Recombinant Human Papillomavirus Quadrivalent Vaccine – Check for trials from TCH’s list of cancer clinical trials now accepting patients.